Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.

Ness N, Andersen S, Khanehkenari MR, Nordbakken CV, Valkov A, Paulsen EE, Nordby Y, Bremnes RM, Donnem T, Busund LT, Richardsen E.

Oncotarget. 2017 Apr 18;8(16):26789-26801. doi: 10.18632/oncotarget.15817.

2.

High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival.

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA.

Int J Cancer. 2017 Jul 1;141(1):184-190. doi: 10.1002/ijc.30726. Epub 2017 Apr 21.

3.

High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.

Nordby Y, Richardsen E, Rakaee M, Ness N, Donnem T, Patel HR, Busund LT, Bremnes RM, Andersen S.

Sci Rep. 2017 Feb 24;7:43378. doi: 10.1038/srep43378.

4.

Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T.

BMC Cancer. 2016 Nov 24;16(1):916. No abstract available.

5.

Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer - a multicenter (in situ hybridization) study.

Andersen S, Richardsen E, Moi L, Donnem T, Nordby Y, Ness N, Holman ME, Bremnes RM, Busund LT.

Sci Rep. 2016 Nov 8;6:36573. doi: 10.1038/srep36573.

6.

Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer.

Rakaee M, Busund LT, Paulsen EE, Richardsen E, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Kilvaer TK.

Oncotarget. 2016 Nov 1;7(44):72184-72196. doi: 10.18632/oncotarget.12360.

7.

Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome.

Grindstad T, Skjefstad K, Andersen S, Ness N, Nordby Y, Al-Saad S, Fismen S, Donnem T, Khanehkenari MR, Busund LT, Bremnes RM, Richardsen E.

Sci Rep. 2016 Sep 9;6:33114. doi: 10.1038/srep33114.

8.

The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival.

Kilvaer TK, Paulsen EE, Khanehkenari MR, Al-Saad S, Johansen RM, Al-Shibli K, Bremnes RM, Busund LT, Donnem T.

Br J Cancer. 2016 May 10;114(10):1145-51. doi: 10.1038/bjc.2016.92. Epub 2016 Apr 7.

9.

Importance of tumor infiltrating lymphocytes in non-small cell lung cancer?

Bremnes RM, Donnem T, Busund LT.

Ann Transl Med. 2016 Apr;4(7):142. doi: 10.21037/atm.2016.03.28. No abstract available.

10.

CD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer.

Paulsen EE, Kilvaer T, Khanehkenari MR, Maurseth RJ, Al-Saad S, Hald SM, Al-Shibli K, Andersen S, Richardsen E, Busund LT, Bremnes R, Donnem T.

Neoplasia. 2015 Nov;17(11):839-48. doi: 10.1016/j.neo.2015.11.004.

11.

Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.

Kilvaer TK, Paulsen EE, Hald SM, Wilsgaard T, Bremnes RM, Busund LT, Donnem T.

PLoS One. 2015 Aug 25;10(8):e0132481. doi: 10.1371/journal.pone.0132481. eCollection 2015. Review.

12.

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.

Kilvaer TK, Khanehkenari MR, Hellevik T, Al-Saad S, Paulsen EE, Bremnes RM, Busund LT, Donnem T, Martinez IZ.

PLoS One. 2015 Aug 7;10(8):e0134965. doi: 10.1371/journal.pone.0134965. eCollection 2015.

13.

Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T.

BMC Cancer. 2015 May 29;15:441. doi: 10.1186/s12885-015-1446-z. Erratum in: BMC Cancer. 2016 Nov 24;16(1):916.

14.

High progesterone receptor expression in prostate cancer is associated with clinical failure.

Grindstad T, Andersen S, Al-Saad S, Donnem T, Kiselev Y, Nordahl Melbø-Jørgensen C, Skjefstad K, Busund LT, Bremnes RM, Richardsen E.

PLoS One. 2015 Feb 27;10(2):e0116691. doi: 10.1371/journal.pone.0116691. eCollection 2015.

15.

Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.

Melbø-Jørgensen C, Ness N, Andersen S, Valkov A, Dønnem T, Al-Saad S, Kiselev Y, Berg T, Nordby Y, Bremnes RM, Busund LT, Richardsen E.

PLoS One. 2014 Nov 17;9(11):e113039. doi: 10.1371/journal.pone.0113039. eCollection 2014.

16.

Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival.

Eilertsen M, Andersen S, Al-Saad S, Kiselev Y, Donnem T, Stenvold H, Pettersen I, Al-Shibli K, Richardsen E, Busund LT, Bremnes RM.

PLoS One. 2014 Sep 16;9(9):e105038. doi: 10.1371/journal.pone.0105038. eCollection 2014.

17.

Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time.

Andersen S, Richardsen E, Nordby Y, Ness N, Størkersen O, Al-Shibli K, Donnem T, Bertilsson H, Busund LT, Angelsen A, Bremnes RM.

BMC Urol. 2014 Jun 14;14:49. doi: 10.1186/1471-2490-14-49.

18.

Stage and tissue-specific prognostic impact of miR-182 in NSCLC.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Busund LT, Bremnes RM.

BMC Cancer. 2014 Feb 27;14:138. doi: 10.1186/1471-2407-14-138.

19.

High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Valkov A, Pedersen MI, Busund LT, Bremnes RM.

BMC Clin Pathol. 2014 Feb 13;14(1):9. doi: 10.1186/1472-6890-14-9.

20.

The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.

Kilvaer TK, Smeland E, Valkov A, Sorbye SW, Bremnes RM, Busund LT, Donnem T.

BMC Clin Pathol. 2014 Jan 20;14(1):5. doi: 10.1186/1472-6890-14-5.

Supplemental Content

Loading ...
Support Center